Safety and immunogenicity of a glycoprotein E gene-deleted bovine herpesvirus 1 strain as a candidate vaccine strain

Weiss, Marcelo; Anziliero, Deniz; Martins, Mathias; Weiblen, Rudi; Flores, Eduardo Furtado

doi:10.1590/s0100-736x2016001100002

Cited by 2 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the recombinant BoHV-1gEΔ proved to be safe for IN immunization of young calves in titers higher than those of most MLV vaccines (10 5-6.5 TCID 50 /mL). This recombinant has been previously shown to be safe for parenteral immunization in high virus titers (10 8 TCID 50 /mL) (WEISS et al, 2016). Unfortunately, we did not address whether the vaccine virus could be transmitted to susceptible contacts, a concern regarding MLV vaccines administered IN (CHASE et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…Gene-deleted BoHV-1 recombinant strains, especially defective in glycoprotein (gE), have been widely used in efforts to control BoHV-1 infection, since they allow for serological differentiation between vaccinated and naturally infected animals (ACKERMANN; ENGELS, 2006;RAAPERI et al, 2014;CHASE et al, 2017). The recombinant BoHV-1gEΔ studied herein has been previously evaluated concerning safety and immunogenicity upon parenteral immunization using live virus or inactivated, adjuvanted virus antigens and serological differentiation was possible by using a gE-specific commercial ELISA (WEISS et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…The recombinant BoHV-1∆gE was constructed of a Brazilian BoHV-1 strain (SV56/90) and was characterized in vitro and in vivo (WEISS et al, 2015(WEISS et al, , 2016. The experiments described herein used passage # 4 of the clone #3 of the recombinant BoHV-1gEΔ.…”

Section: Viruses and Cellsmentioning

confidence: 99%

“…Nasal swabs were submitted to virus isolation in MDBK cells as described previously (WEISS et al, 2010); positive samples were quantitated by limiting dilution and virus titers were expressed as log 10 TCID 50 /mL. Serum samples obtained at different times after immunization were tested for virus neutralizing (VN) antibodies against BoHV-1 by VN assay, using the homologous virus as the challenge virus (WEISS et al, 2016). Titers were expressed as the reciprocal of the highest dilution that prevented virus replication.…”

Section: Animal Studymentioning

confidence: 99%

“…Most differential vaccines (differentiating infected from vaccinated animals, DIVA) are based on a single deletion of the glycoprotein E (gE) gene (BOSCH et al, 1996;EL-KHOLY et al, 2013;FRANCO et al, 2002;KAASHOEK et al, 1996; VAN ENGELENBURG et al, 1994;WEISS et al, 2015), whereas some contain deletion on the glycoprotein C (gC) gene and/or an additional deletion for further attenuation, usually the thymidine kinase (tk) gene (FLORES et al, 1993;KAASHOEK et al, 1996). In this line, a gE-negative BoHV-1 recombinant (BoHV-1gEΔ) has been constructed out of a Brazilian BoHV-1 strain and evaluated regarding to safety, immunogenicity and potential serological differentiation (WEISS et al, 2015(WEISS et al, , 2016.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A glycoprotein E gene-deleted bovine alphaherpesvirus 1 strain is attenuated and immunogenic for calves with passive immunity upon intranasal immunization

et al. 2023

Self Cite

View full text Add to dashboard Cite

Vaccination has been used to prevent the losses associated with Bovine alphaherpesvirus 1 (BoHV-1) infection but passively acquired antibodies may compromise vaccine efficacy. Intranasal immunization (IN) of calves with modified live viral BoHV-1 vaccines has proven to overcome the acquired passive antibodies and confer adequate protection. Herein, we evaluated the safety and immunogenicity of a glycoprotein E-deleted Brazilian BoHV-1 strain (BoHV-1gEΔ) for IN immunization of calves. Ten 1-to-2 months-old calves with virus-neutralizing titers (VN) ranging from 2-64 were immunized IN with viable BoHV-1gEΔ (107.1 TCID50) and four remained as unvaccinated controls (VN titers 8-32). After IN immunization, calves presented a transient (2-6 days) mild nasal secretion and shed the vaccine virus in nasal secretions in low titers (<102.6TCID50/mL) for 4-8 days. Interestingly, the vaccinated calves did not show an increase in VN titers after vaccination. Rather, they presented a gradual reduction in serum VN antibodies in the following weeks - similarly to unvaccinated controls. Upon IN challenge with a virulent heterologous BoHV-1 strain at day 55 post-immunization (107.63TCID50), vaccinated calves shed significantly less virus from day 6 post-challenge onwards (p < 0.07) and for a shorter period of time than the controls (p < 0.0024). Importantly, both the duration and intensity of clinical signs were reduced in vaccinated animals. In addition, vaccinated calves showed an abrupt raise in VN titers post-challenge, indicating adequate immunological priming by vaccination. In summary, immunization of calves harboring passive antibodies with BoHV-1gEΔ by the IN route was able to prime the immunity to afford partial virological and clinical protection upon challenge.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Viruses and Cellsmentioning

confidence: 99%

Section: Animal Studymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A glycoprotein E gene-deleted bovine alphaherpesvirus 1 strain is attenuated and immunogenic for calves with passive immunity upon intranasal immunization

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Some aspects of effective control of Bovine infectious rhinotracheitis in European countries

Kornieikov

Stegniy

Oleshko

et al. 2021

Veterinary Medicine: Inter-Departmental Subject Scientific Collection

View full text Add to dashboard Cite

Data on the epizootic situation concerning bovine infectious rhinotracheitis in the countries of the European continent are presented. Most of the countries that are members of the World Organization for Animal Health have implemented anti-epidemic measures on their territory, which include observation, reporting, monitoring or screening, as well as control of the movement of animals within the country and precautionary measures at the border. It has been noted that permanent safety in relation to the disease is possible only under the conditions of implementation of mandatory control measures at the state level, which are based on the removal of seropositive animals infected with an epizootic strain of the virus from herds simultaneously with or without the use of vaccines. In most countries of the European Union, IRT virus eradication programs have been implemented, which are based on research and removal strategies, as well as differentiation of vaccinated from infected animals. As the experience of the Scandinavian countries has shown, the most effective scheme is the eradication of the IRT pathogen by slaughtering infected animals, but this is only possible under conditions of a low level of livestock infection. The most economically feasible strategy for controlling IRT in herds with high levels of infection is the use of marker vaccines, followed by differentiation of vaccinated animals from infected ones and removal of the latter from the herd. When a low level of herd seropositivity is reached, it is advisable to implement a detection and slaughter strategy

show abstract

Safety and immunogenicity of a glycoprotein E gene-deleted bovine herpesvirus 1 strain as a candidate vaccine strain

Cited by 2 publications

References 27 publications

A glycoprotein E gene-deleted bovine alphaherpesvirus 1 strain is attenuated and immunogenic for calves with passive immunity upon intranasal immunization

A glycoprotein E gene-deleted bovine alphaherpesvirus 1 strain is attenuated and immunogenic for calves with passive immunity upon intranasal immunization

Some aspects of effective control of Bovine infectious rhinotracheitis in European countries

Contact Info

Product

Resources

About